In April 2020, the article 'Identification of the Clinical Development Candidate MRTX849, a Covalent KRAS G12C Inhibitor for the Treatment of Cancer' ( describing the discovery of MRTX849 as a potent, selective covalent inhibitor of KRAS G12C, that bind in the switch-II pocket of KRAS, was published. Now this drug candidate is in a Phase 1/2 trials in patients with advanced solid tumors (Non-Small Cell Lung Cancer and Colorectal Cancer) with KRAS G12C mutation. MRTX849 contains 5H,6H,7H,8H-pyrido[3,4-d]pyrimidine moiety in its backbone. We have made a set of compounds, which contain such part – the perfect start for your research!